Currently, there are 300.60M common shares owned by the public and among those 298.26M shares have been available to trade.
Insiders at the company have transacted a total of 10 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 8 of these insider trades were purchases, accounting for 46,108 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 17,171 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of 0.85% and 7.65% over the past three months. BRX shares are trading -2.62% year to date (YTD), with the 12-month market performance down to -1.82% lower. It has a 12-month low price of $19.40 and touched a high of $24.47 over the same period. BRX has an average intraday trading volume of 2.26 shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 0.51%, -0.64%, and 4.17% respectively.
Institutional ownership of Brixmor Property Group Inc (NYSE: BRX) shares accounts for 102.68% of the company’s 300.60M shares outstanding.
It has a market capitalization of $6.81B and a beta (3y monthly) value of 1.51. The stock’s trailing 12-month PE ratio is 22.48, while the earnings-per-share (ttm) stands at $1.01. The company has a debt-to-equity ratio at 1.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.39% over the week and 2.08% over the month.
Analysts forecast that Brixmor Property Group Inc (BRX) will achieve an EPS of $ImmunityBio, Inc. for the current quarter, $4.23 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $BioCryst Pharmaceuticals, Inc. while analysts give the company a high EPS estimate of $Boston Scientific Corporation. Comparatively, EPS for the current quarter was $Biodexa Pharmaceuticals plc a year ago. Earnings per share for the fiscal year are expected to decrease by -18.15%, and 6.20% over the next financial year. EPS should shrink at an annualized rate of -10.65% over the next five years, compared to -3.63% over the past 5-year period.
Looking at the support for the BRX, a number of firms have released research notes about the stock. Deutsche Bank stated their Buy rating for the stock in a research note on January 30, 2024, with the firm’s price target at $27.
